MNKD vs ORMP
MNKD: MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic and orphan lung diseases. ORMP: Oramed is a clinical-stage pharmaceutical company developing oral insulin delivery technology while actively investing in healthcare companies to diversify capital allocation.
Side-by-side fundamentals
| Metric | MNKD | ORMP | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.84 | $4.02 | |
| Market cap as of 2026-07-23 | $1.2B | $165M | |
| P/E as of 2026-07-23 | 212.36 | 1.50 | ORMP lower |
| Net margin as of 2026-07-23 | -6.4% | -838.4% | MNKD higher |
| Gross margin as of 2026-07-23 | +78.4% | n/a | |
| Operating margin as of 2026-07-23 | +4.1% | -1070.4% | MNKD higher |
| ROE as of 2026-07-23 | -297.7% | +55.1% | ORMP higher |
| ROA as of 2026-07-23 | -3.8% | +49.8% | ORMP higher |
| Debt / equity as of 2026-07-23 | 9.95 | 0.00 | ORMP lower |
| Revenue growth (YoY) as of 2026-07-23 | +21.2% | -30.9% | MNKD higher |
| Revenue CAGR (3y) SEC XBRL | +51.8% | -7.3% | MNKD higher |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 1.12 | 1.16 | |
| 1-year return as of 2026-07-22 close | -2.3% | +88.7% | ORMP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.